NEW YORK ( TheStreet) -- CHANGE IN RATINGSAmgen ( AMGN) rated new Buy at Stifel Nicolaus. $68 price target. Company has the only major new product among its peers. Celanese ( CE) upgraded at Citigroup from Hold to Buy. $35 price target. Company is growing in China, which should also help keep costs down. Celgene ( CELG) rated new Buy at Stifel Nicolaus. $71 price target. Company has superior growth prospects. Gilead Sciences ( GILD) rated new Hold at Stifel Nicolaus. Valuation call, as the company is facing patent expirations. Idexx Laboratories ( IDXX) rated new Market Perform at Leerink. Stock is already pricing in the company's organic growth potential. Skilled Healthcare Group ( SKH) upgraded at Credit Suisse to Neutral from Underperform as the company agreed to a $50 million settlement in the Lavender case. The settlement was significantly lower than the Street's expectation, Credit Suisse said. Price target increased to $5 from $2. Teva Pharmaceutical ( TEVA) upgraded at Oppenheimer from Perform to Outperform, Oppenheimer said. $65 price target. Effexor XR launch was strong and the company should post better earnings in the second half of 2010. Tellabs ( TLAB) downgraded at Soleil from Buy to Hold. $8 price target. Estimates also cut, as the company is losing market share at Soleil. Valspar ( VAL) was downgraded at Citigroup from Buy to Hold. $32 price target. Paint sales tailed off toward the end of summer, as the housing market soured.
Manpower ( MAN) estimates, target lowered at Deutsche Bank. Shares of MAN now seen reaching $62, according to Deutsche Bank. Estimates also cut, given lower growth in France. Buy rating. Navistar ( NAV) price target trimmed at Barclays. NAV price target lowered to $47 from $54. Military drives third-quarter beat, and fourth-quarter revenue headwind remains, Barclays said. 2010 and 2011 EPS estimates cut to $2.85 and $3.75, respectively. Maintain Equal Weight rating. Phillips-Van Heusen ( PVH) estimates raised at Credit Suisse. 2011 and 2012 EPS estimates increased to $3.75 and $4.80, respectively. Strong sales trend and right mix of channels, Credit Suisse said. Maintain Neutral rating and $58 price target. Phillips-Van Heusen ( PVH) numbers upped at Citigroup. PVH estimates were boosted through 2012, Citigroup said. Company continues to execute in a difficult environment. Hold rating and new $63 price target. Silicon Laboratories ( SLAB) numbers cut at Citigroup. Shares of SLAB now seen reaching $36, according to Citigroup. Estimates also lowered, to match the company's new guidance. Hold rating. Shanda Games ( SNDA) target lowered at ThinkEquity. Shares of SNDA now seen reaching $6, according to ThinkEquity. Company is facing disruptions with its top game. Hold rating. United Natural Foods ( UNFI) estimate trimmed at Barclays. UNFI 2011 EPS estimate reduced to $1.79 from $1.89. Gross margin pressures but revenue growth remains strong, Barclays said. Maintain Equal Weight rating and $33 price target.